Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus

Journal of Immunology

Volumn 191, Issue 11, 2013, Pages 5515-5523

  Stenqvist, Ann Christin ^a   Nagaeva, Olga ^a   Baranov, Vladimir ^a   Mincheva Nilsson, Lucia ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL AGGREGATION; CELL COMPARTMENTALIZATION; CELLULAR SECRETION; EMBRYO; ENDOSOME; EXOSOME; EXTRACELLULAR SPACE; FEMALE; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOELECTRON MICROSCOPY; IN VITRO STUDY; LEUKEMIA CELL LINE; MEMBRANE VESICLE; MULTIVESICULAR BODY; PLACENTA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYNCYTIOTROPHOBLAST;

EID: 84888367722     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301885     Document Type: Article

References (61)

1. Mincheva-Nilsson, L. 2006. Immune cells and molecules in pregnancy: friends or foes to the fetus? Expert Rev. Clin. Immunol. 2: 457-470.
2. Sharp, A. N., A. E. Heazell, I. P. Crocker, and G. Mor. 2010. Placental apoptosis in health and disease. Am. J. Reprod. Immunol. 64: 159-169.
3. Huppertz, B., H. G. Frank, J. C. Kingdom, F. Reister, and P. Kaufmann. 1998. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem. Cell Biol. 110: 495-508.
4. Mor, G., S. Straszewski, and M. Kamsteeg. 2002. Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem. Pharmacol. 64: 1305-1315.
5. Mincheva-Nilsson, L., O. Nagaeva, K. G. Sundqvist, M. L. Hammarström, S. Hammarström, and V. Baranov. 2000. γδ T cells of human early pregnancy decidua: evidence for cytotoxic potency. Int. Immunol. 12: 585-596.
6. Clark, D. A. 2005. Tolerance signaling molecules. Chem. Immunol. Allergy 89: 36-48.
7. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281: 1305-1308.
8. Russo, M., A. Mupo, C. Spagnuolo, and G. L. Russo. 2010. Exploring death receptor pathways as selective targets in cancer therapy. Biochem. Pharmacol. 80: 674-682.
9. Green, D. R., and T. A. Ferguson. 2001. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2: 917-924.
10. Lettau, M., M. Paulsen, H. Schmidt, and O. Janssen. 2011. Insights into the molecular regulation of FasL (CD178) biology. Eur. J. Cell Biol. 90: 456-466.
11. Holler, N., A. Tardivel, M. Kovacsovics-Bankowski, S. Hertig, O. Gaide, F. Martinon, A. Tinel, D. Deperthes, S. Calderara, T. Schulthess, et al. 2003. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23: 1428-1440.
12. Vargo-Gogola, T., H. C. Crawford, B. Fingleton, and L. M. Matrisian. 2002. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 408: 155-161.
13. Hymowitz, S. G., M. P. O'Connell, M. H. Ultsch, A. Hurst, K. Totpal, A. Ashkenazi, A. M. de Vos, and R. F. Kelley. 2000. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39: 633-640.
14. Martinez-Lostao, L., I. Marzo, A. Anel, and J. Naval. 2012. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem. Pharmacol. 83: 1475-1483.
15. Martínez-Lorenzo, M. J., A. Anel, S. Gamen, I. Monle n, P. Lasierra, L. Larrad, A. Piñeiro, M. A. Alava, and J. Naval. 1999. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 163: 1274-1281.
16. Hammer, A., and G. Dohr. 2000. Expression of Fas-ligand in first trimester and term human placental villi. J. Reprod. Immunol. 46: 83-90.
17. Phillips, T. A., J. Ni, G. Pan, S. M. Ruben, Y. F. Wei, J. L. Pace, and J. S. Hunt. 1999. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J. Immunol. 162: 6053-6059.
18. Bai, X., J. L. Williams, S. L. Greenwood, P. N. Baker, J. D. Aplin, and I. P. Crocker. 2009. A placental protective role for trophoblast-derived TNF-related apoptosis-inducing ligand (TRAIL). Placenta 30: 855-860.
19. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94: 3943-3947.
20. Roh, C. R., J. W. Lee, B. H. Kang, S. H. Yang, B. G. Kim, D. S. Bae, J. H. Kim, and J. H. Lee. 2002. Differential expressions of Fas and Fas ligand in human placenta. J. Korean Med. Sci. 17: 213-216.
21. Abrahams, V. M., S. L. Straszewski-Chavez, S. Guller, and G. Mor. 2004. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol. Hum. Reprod. 10: 55-63.
22. Frängsmyr, L., V. Baranov, O. Nagaeva, U. Stendahl, L. Kjellberg, and L. Mincheva-Nilsson. 2005. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol. Hum. Reprod. 11: 35-41.
23. Chaput, N., and C. Théry. 2011. Exosomes: immune properties and potential clinical implementations. Semin. Immunopathol. 33: 419-440.
24. Clayton, A., and M. D. Mason. 2009. Exosomes in tumour immunity. Curr. Oncol. 16: 46-49.
25. Mincheva-Nilsson, L., and V. Baranov. 2010. The role of placental exosomes in reproduction. Am. J. Reprod. Immunol. 63: 520-533.
26. Stenqvist, A. C., T. Chen, M. Hedlund, T. Dimova, O. Nagaeva, L. Kjellberg, E. Innala, and L. Mincheva-Nilsson. 2008. An efficient optimized method for isolation of villous trophoblast cells from human early pregnancy placenta suitable for functional and molecular studies. Am. J. Reprod. Immunol. 60: 33-42.
27. Hedlund, M., A. C. Stenqvist, O. Nagaeva, L. Kjellberg, M. Wulff, V. Baranov, and L. Mincheva-Nilsson. 2009. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J. Immunol. 183: 340-351.
28. Mincheva-Nilsson, L., O. Nagaeva, T. Chen, U. Stendahl, J. Antsiferova, I. Mogren, J. Hernestål, and V. Baranov. 2006. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J. Immunol. 176: 3585-3592.
29. Lamparski, H. G., A. Metha-Damani, J. Y. Yao, S. Patel, D. H. Hsu, C. Ruegg, and J. B. Le Pecq. 2002. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods 270: 211-226.
30. Mari, M. M., M. V. Bujny, D. Zeuschner, W. J. Geerts, J. Griffith, C. M. Petersen, P. J. Cullen, J. Klumperman, and H. J. Geuze. 2008. SNX1 defines an early endosomal recycling exit for sortilin and mannose 6-phosphate receptors. Traffic 9: 380-393.
31. Andreola, G., L. Rivoltini, C. Castelli, V. Huber, P. Perego, P. Deho, P. Squarcina, P. Accornero, F. Lozupone, L. Lugini, et al. 2002. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195: 1303-1316.
32. Smith, A. J., J. R. Pfeiffer, J. Zhang, A. M. Martinez, G. M. Griffiths, and B. S. Wilson. 2003. Microtubule-dependent transport of secretory vesicles in RBL-2H3 cells. Traffic 4: 302-312.
33. Jodo, S., A.M. Hohlbaum, S. Xiao, D. Chan, D. Strehlow, D.H. Sherr, A. Marshak-Rothstein, and S.T. Ju. 2000. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity. J. Immunol. 165: 5487-5494.
34. Monleón, I., M. J. Martínez-Lorenzo, L. Monteagudo, P. Lasierra, M. Taulés, M. Iturralde, A. Piñeiro, L. Larrad, M. A. Alava, J. Naval, and A. Anel. 2001. Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J. Immunol. 167: 6736-6744.
35. Bossi, G., and G. M. Griffiths. 1999. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5: 90-96.
36. Blott, E. J., G. Bossi, R. Clark, M. Zvelebil, and G. M. Griffiths. 2001. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J. Cell Sci. 114: 2405-2416.
37. Zuccato, E., E. J. Blott, O. Holt, S. Sigismund, M. Shaw, G. Bossi, and G. M. Griffiths. 2007. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J. Cell Sci. 120: 191-199.
38. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187: 1205-1213.
39. Shudo, K., K. Kinoshita, R. Imamura, H. Fan, K. Hasumoto, M. Tanaka, S. Nagata, and T. Suda. 2001. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur. J. Immunol. 31: 2504-2511.
40. Hohlbaum, A. M., S. Moe, and A. Marshak-Rothstein. 2000. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191: 1209-1220.
41. Gregory, M. S., A. C. Repp, A. M. Holhbaum, R. R. Saff, A. Marshak-Rothstein, and B. R. Ksander. 2002. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 169: 2727-2735.
42. Kang, S. M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3: 738-743.
43. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186: 2045-2050.
44. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189: 1343-1354.
45. Lünemann, J. D., S. Waiczies, S. Ehrlich, U. Wendling, B. Seeger, T. Kamradt, and F. Zipp. 2002. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J. Immunol. 168: 4881-4888.
46. Kelly, M. M., B. D. Hoel, and C. Voelkel-Johnson. 2002. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol. Ther. 1: 520-527.
47. Wajant, H., D. Moosmayer, T. Wüest, T. Bartke, E. Gerlach, U. Schönherr, N. Peters, P. Scheurich, and K. Pfizenmaier. 2001. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20: 4101-4106.
48. Munich, S., A. Sobo-Vujanovic,W. J. Buchser, D. Beer-Stolz, and N. L. Vujanovic. 2012. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Onco Immunology 1: 1074-1083.
49. Alonso, R., M. C. Rodríguez, J. Pindado, E. Merino, I. Mérida, and M. Izquierdo. 2005. Diacylglycerol kinase a regulates the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. J. Biol. Chem. 280: 28439-28450.
50. Martínez-Lorenzo, M. J., A. Anel, M. A. Alava, A. Piñeiro, J. Naval, P. Lasierra, and L. Larrad. 2004. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles: possible contribution to tumor counterattack. Exp. Cell Res. 295: 315-329.
51. Peng, P., Y. Yan, and S. Keng. 2011. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol. Rep. 25: 749-762.
52. Martínez-Lorenzo, M. J., A. Anel, B. Saez-Gutierrez, M. Royo-Cañas, A. Bosque, M. A. Alava, A. Piñeiro, P. Lasierra, J. Asín-Ungría, and L. Larrad. 2007. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin. Immunol. 122: 28-40.
53. Sträter, J., H. Walczak, C. Hasel, I. Melzner, F. Leithäuser, and P. Möller. 2001. CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ. 8: 273-278.
54. Clayton, A. 2012. Cancer cells use exosomes as tools to manipulate immunity and the microenvironment. OncoImmunology 1: 78-80.
55. Lingwood, D., and K. Simons. 2010. Lipid rafts as a membrane-organizing principle. Science 327: 46-50.
56. Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
57. Voss, M., M. Lettau, M. Paulsen, and O. Janssen. 2008. Posttranslational regulation of Fas ligand function. Cell Commun. Signal. 6: 11.
58. Benhar, I., A. London, and M. Schwartz. 2012. The privileged immunity of immune privileged organs: the case of the eye. Front Immunol 3: 296.
59. Lee, H. O., J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson. 2002. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J. Immunol. 169: 4739-4744.
60. Taylor, D. D., S. Akyol, and C. Gercel-Taylor. 2006. Pregnancy-associated exosomes and their modulation of T cell signaling. J. Immunol. 176: 1534-1542.
61. Knight, M., C. W. G. Redman, E. A. Linton, and I. L. Sargent. 1998. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol. 105: 632-640.